Literature DB >> 34228725

SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variants.

Fiona Tea1, Alberto Ospina Stella2, Anupriya Aggarwal2, David Ross Darley3,4, Deepti Pilli1, Daniele Vitale5, Vera Merheb1, Fiona X Z Lee1, Philip Cunningham6, Gregory J Walker7, Christina Fichter2, David A Brown5,7, William D Rawlinson7,8,9, Sonia R Isaacs7, Vennila Mathivanan2, Markus Hoffmann10,11, Stefan Pöhlman10,11, Ohan Mazigi4,12, Daniel Christ4,12, Dominic E Dwyer7,13,14, Rebecca J Rockett13,14, Vitali Sintchenko7,13,14,15, Veronica C Hoad16, David O Irving16,17, Gregory J Dore2,3, Iain B Gosbell16,18, Anthony D Kelleher2, Gail V Matthews2,3, Fabienne Brilot1,14,19,20, Stuart G Turville2.   

Abstract

The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) antibody neutralization response and its evasion by emerging viral variants and variant of concern (VOC) are unknown, but critical to understand reinfection risk and breakthrough infection following vaccination. Antibody immunoreactivity against SARS-CoV-2 antigens and Spike variants, inhibition of Spike-driven virus-cell fusion, and infectious SARS-CoV-2 neutralization were characterized in 807 serial samples from 233 reverse transcription polymerase chain reaction (RT-PCR)-confirmed Coronavirus Disease 2019 (COVID-19) individuals with detailed demographics and followed up to 7 months. A broad and sustained polyantigenic immunoreactivity against SARS-CoV-2 Spike, Membrane, and Nucleocapsid proteins, along with high viral neutralization, was associated with COVID-19 severity. A subgroup of "high responders" maintained high neutralizing responses over time, representing ideal convalescent plasma donors. Antibodies generated against SARS-CoV-2 during the first COVID-19 wave had reduced immunoreactivity and neutralization potency to emerging Spike variants and VOC. Accurate monitoring of SARS-CoV-2 antibody responses would be essential for selection of optimal responders and vaccine monitoring and design.

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34228725     DOI： 10.1371/journal.pmed.1003656

Source DB:  PubMed          Journal:  PLoS Med        ISSN： 1549-1277            Impact factor:   11.069


  49 in total

1.  Revealing COVID-19 transmission in Australia by SARS-CoV-2 genome sequencing and agent-based modeling.

Authors:  Rebecca J Rockett; Alicia Arnott; Connie Lam; Rosemarie Sadsad; Verlaine Timms; Karen-Ann Gray; John-Sebastian Eden; Sheryl Chang; Mailie Gall; Jenny Draper; Eby M Sim; Nathan L Bachmann; Ian Carter; Kerri Basile; Roy Byun; Matthew V O'Sullivan; Sharon C-A Chen; Susan Maddocks; Tania C Sorrell; Dominic E Dwyer; Edward C Holmes; Jen Kok; Mikhail Prokopenko; Vitali Sintchenko
Journal:  Nat Med       Date:  2020-07-09       Impact factor: 53.440

2.  Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients.

Authors:  Anita S Iyer; Forrest K Jones; Ariana Nodoushani; Jason B Harris; Richelle C Charles; Meagan Kelly; Margaret Becker; Damien Slater; Rachel Mills; Erica Teng; Mohammad Kamruzzaman; Wilfredo F Garcia-Beltran; Michael Astudillo; Diane Yang; Tyler E Miller; Elizabeth Oliver; Stephanie Fischinger; Caroline Atyeo; A John Iafrate; Stephen B Calderwood; Stephen A Lauer; Jingyou Yu; Zhenfeng Li; Jared Feldman; Blake M Hauser; Timothy M Caradonna; John A Branda; Sarah E Turbett; Regina C LaRocque; Guillaume Mellon; Dan H Barouch; Aaron G Schmidt; Andrew S Azman; Galit Alter; Edward T Ryan
Journal:  Sci Immunol       Date:  2020-10-08

3.  Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19.

Authors:  Michael J Joyner; Rickey E Carter; Jonathon W Senefeld; Stephen A Klassen; John R Mills; Patrick W Johnson; Elitza S Theel; Chad C Wiggins; Katelyn A Bruno; Allan M Klompas; Elizabeth R Lesser; Katie L Kunze; Matthew A Sexton; Juan C Diaz Soto; Sarah E Baker; John R A Shepherd; Noud van Helmond; Nicole C Verdun; Peter Marks; Camille M van Buskirk; Jeffrey L Winters; James R Stubbs; Robert F Rea; David O Hodge; Vitaly Herasevich; Emily R Whelan; Andrew J Clayburn; Kathryn F Larson; Juan G Ripoll; Kylie J Andersen; Matthew R Buras; Matthew N P Vogt; Joshua J Dennis; Riley J Regimbal; Philippe R Bauer; Janis E Blair; Nigel S Paneth; DeLisa Fairweather; R Scott Wright; Arturo Casadevall
Journal:  N Engl J Med       Date:  2021-01-13       Impact factor: 91.245

4.  Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection.

Authors:  Jennifer M Dan; Jose Mateus; Yu Kato; Kathryn M Hastie; Esther Dawen Yu; Caterina E Faliti; Alba Grifoni; Sydney I Ramirez; Sonya Haupt; April Frazier; Catherine Nakao; Vamseedhar Rayaprolu; Stephen A Rawlings; Bjoern Peters; Florian Krammer; Viviana Simon; Erica Ollmann Saphire; Davey M Smith; Daniela Weiskopf; Alessandro Sette; Shane Crotty
Journal:  Science       Date:  2021-01-06       Impact factor: 47.728

5.  Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity.

Authors:  Markus Hoffmann; Heike Hofmann-Winkler; Joan C Smith; Nadine Krüger; Prerna Arora; Lambert K Sørensen; Ole S Søgaard; Jørgen Bo Hasselstrøm; Michael Winkler; Tim Hempel; Lluís Raich; Simon Olsson; Olga Danov; Danny Jonigk; Takashi Yamazoe; Katsura Yamatsuta; Hirotaka Mizuno; Stephan Ludwig; Frank Noé; Mads Kjolby; Armin Braun; Jason M Sheltzer; Stefan Pöhlmann
Journal:  EBioMedicine       Date:  2021-03-04       Impact factor: 11.205

6.  Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population.

Authors:  Sabra L Klein; Andrew Pekosz; Han-Sol Park; Rebecca L Ursin; Janna R Shapiro; Sarah E Benner; Kirsten Littlefield; Swetha Kumar; Harnish Mukesh Naik; Michael J Betenbaugh; Ruchee Shrestha; Annie A Wu; Robert M Hughes; Imani Burgess; Patricio Caturegli; Oliver Laeyendecker; Thomas C Quinn; David Sullivan; Shmuel Shoham; Andrew D Redd; Evan M Bloch; Arturo Casadevall; Aaron Ar Tobian
Journal:  J Clin Invest       Date:  2020-11-02       Impact factor: 14.808

7.  Significantly Decreased Mortality in a Large Cohort of Coronavirus Disease 2019 (COVID-19) Patients Transfused Early with Convalescent Plasma Containing High-Titer Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike Protein IgG.

Authors:  Eric Salazar; Paul A Christensen; Edward A Graviss; Duc T Nguyen; Brian Castillo; Jian Chen; Bevin V Lopez; Todd N Eagar; Xin Yi; Picheng Zhao; John Rogers; Ahmed Shehabeldin; David Joseph; Faisal Masud; Christopher Leveque; Randall J Olsen; David W Bernard; Jimmy Gollihar; James M Musser
Journal:  Am J Pathol       Date:  2020-11-04       Impact factor: 4.307

8.  Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant.

Authors:  Leonid Yurkovetskiy; Xue Wang; Kristen E Pascal; Christopher Tomkins-Tinch; Thomas P Nyalile; Yetao Wang; Alina Baum; William E Diehl; Ann Dauphin; Claudia Carbone; Kristen Veinotte; Shawn B Egri; Stephen F Schaffner; Jacob E Lemieux; James B Munro; Ashique Rafique; Abhi Barve; Pardis C Sabeti; Christos A Kyratsous; Natalya V Dudkina; Kuang Shen; Jeremy Luban
Journal:  Cell       Date:  2020-09-15       Impact factor: 66.850

9.  Genome-wide CRISPR Screens Reveal Host Factors Critical for SARS-CoV-2 Infection.

Authors:  Jin Wei; Mia Madel Alfajaro; Peter C DeWeirdt; Ruth E Hanna; William J Lu-Culligan; Wesley L Cai; Madison S Strine; Shang-Min Zhang; Vincent R Graziano; Cameron O Schmitz; Jennifer S Chen; Madeleine C Mankowski; Renata B Filler; Neal G Ravindra; Victor Gasque; Fernando J de Miguel; Ajinkya Patil; Huacui Chen; Kasopefoluwa Y Oguntuyo; Laura Abriola; Yulia V Surovtseva; Robert C Orchard; Benhur Lee; Brett D Lindenbach; Katerina Politi; David van Dijk; Cigall Kadoch; Matthew D Simon; Qin Yan; John G Doench; Craig B Wilen
Journal:  Cell       Date:  2020-10-20       Impact factor: 66.850

10.  Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity.

Authors:  Ellen Shrock; Eric Fujimura; Tomasz Kula; Richard T Timms; I-Hsiu Lee; Yumei Leng; Matthew L Robinson; Brandon M Sie; Mamie Z Li; Yuezhou Chen; Jennifer Logue; Adam Zuiani; Denise McCulloch; Felipe J N Lelis; Stephanie Henson; Daniel R Monaco; Meghan Travers; Shaghayegh Habibi; William A Clarke; Patrizio Caturegli; Oliver Laeyendecker; Alicja Piechocka-Trocha; Jonathan Z Li; Ashok Khatri; Helen Y Chu; Alexandra-Chloé Villani; Kyle Kays; Marcia B Goldberg; Nir Hacohen; Michael R Filbin; Xu G Yu; Bruce D Walker; Duane R Wesemann; H Benjamin Larman; James A Lederer; Stephen J Elledge
Journal:  Science       Date:  2020-09-29       Impact factor: 63.714
View more
  32 in total

Review 1.  Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection.

Authors:  Yu-Chyi Hwang; Ruei-Min Lu; Shih-Chieh Su; Pao-Yin Chiang; Shih-Han Ko; Feng-Yi Ke; Kang-Hao Liang; Tzung-Yang Hsieh; Han-Chung Wu
Journal:  J Biomed Sci       Date:  2022-01-04       Impact factor: 8.410

2.  Technical performance of a lateral flow immunoassay for detection of anti-SARS-CoV-2 IgG in the outpatient follow-up of non-severe cases and at different times after vaccination: comparison with enzyme and chemiluminescent immunoassays.

Authors:  Gabriel Acca Barreira; Emilly Henrique Dos Santos; Maria Fernanda Bádue Pereira; Karen Alessandra Rodrigues; Mussya Cisotto Rocha; Kelly Aparecida Kanunfre; Heloisa Helena de Sousa Marques; Thelma Suely Okay; Adriana Pasmanik Eisencraft; Alfio Rossi Junior; Alice Lima Fante; Aline Pivetta Cora; Amelia Gorete A de Costa Reis; Ana Paula Scoleze Ferrer; Anarella Penha Meirelles de Andrade; Andreia Watanabe; Angelina Maria Freire Gonçalves; Aurora Rosaria Pagliara Waetge; Camila Altenfelder Silva; Carina Ceneviva; Carolina Dos Santos Lazari; Deipara Monteiro Abellan; Ester Cerdeira Sabino; Fabíola Roberta Marim Bianchini; Flávio Ferraz de Paes Alcantara; Gabriel Frizzo Ramos; Gabriela Nunes Leal; Isadora Souza Rodriguez; João Renato Rebello Pinho; Jorge David Avaizoglou Carneiro; Jose Albino Paz; Juliana Carvalho Ferreira; Juliana Ferreira Ferranti; Juliana de Oliveira Achili Ferreira; Juliana Valéria de Souza Framil; Katia Regina da Silva; Karina Lucio de Medeiros Bastos; Karine Vusberg Galleti; Lilian Maria Cristofani; Lisa Suzuki; Lucia Maria Arruda Campos; Maria Beatriz de Moliterno Perondi; Maria de Fatima Rodrigues Diniz; Maria Fernanda Mota Fonseca; Mariana Nutti de Almeida Cordon; Mariana Pissolato; Marina Silva Peres; Marlene Pereira Garanito; Marta Imamura; Mayra de Barros Dorna; Michele Luglio; Nadia Emi Aikawa; Natalia Viu Degaspare; Neusa Keico Sakita; Nicole Lee Udsen; Paula Gobi Scudeller; Paula Vieira de Vincenzi Gaiolla; Rafael da Silva Giannasi Severini; Regina Maria Rodrigues; Ricardo Katsuya Toma; Ricardo Iunis Citrangulo de Paula; Patricia Palmeira; Silvana Forsait; Sylvia Costa Lima Farhat; Tânia Miyuki Shimoda Sakano; Vera Hermina Kalika Koch; Vilson Cobello Junior
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2022-07-13       Impact factor: 2.169

3.  Homogeneous surrogate virus neutralization assay to rapidly assess neutralization activity of anti-SARS-CoV-2 antibodies.

Authors:  Sun Jin Kim; Zhong Yao; Morgan C Marsh; Debra M Eckert; Michael S Kay; Anna Lyakisheva; Maria Pasic; Aiyush Bansal; Chaim Birnboim; Prabhat Jha; Yannick Galipeau; Marc-André Langlois; Julio C Delgado; Marc G Elgort; Robert A Campbell; Elizabeth A Middleton; Igor Stagljar; Shawn C Owen
Journal:  Nat Commun       Date:  2022-07-01       Impact factor: 17.694

4.  Human Intramuscular Hyperimmune Gamma Globulin (hIHGG) Anti-SARS-CoV-2-Characteristics of Intermediates and Final Product.

Authors:  Elzbieta Lachert; Joanna Lasocka; Artur Bielawski; Ewa Sulkowska; Katarzyna Guz; Krzysztof Pyrc; Agnieszka Dabrowska; Agata Wawryniuk-Malmon; Magdalena Letowska; Krzysztof Tomasiewicz; Piotr Grabarczyk
Journal:  Viruses       Date:  2022-06-17       Impact factor: 5.818

Review 5.  Coronavirus Disease 2019 Vaccinations in Patients With Chronic Liver Disease and Liver Transplant Recipients: An Update.

Authors:  Pimsiri Sripongpun; Nawamin Pinpathomrat; Jackrapong Bruminhent; Apichat Kaewdech
Journal:  Front Med (Lausanne)       Date:  2022-06-22

Review 6.  Neutralising antibody escape of SARS-CoV-2 spike protein: Risk assessment for antibody-based Covid-19 therapeutics and vaccines.

Authors:  Daniele Focosi; Fabrizio Maggi
Journal:  Rev Med Virol       Date:  2021-03-16       Impact factor: 11.043

7.  Dichotomy between the humoral and cellular responses elicited by mRNA and adenoviral vector vaccines against SARS-CoV-2.

Authors:  Rahul Ukey; Natalie Bruiners; Hridesh Mishra; Pankaj K Mishra; Deborah McCloskey; Alberta Onyuka; Fei Chen; Abraham Pinter; Daniela Weiskopf; Alessandro Sette; Jason Roy; Sunanda Gaur; Maria Laura Gennaro
Journal:  BMC Med       Date:  2022-01-25       Impact factor: 8.775

8.  Immunogenicity and Safety of an Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population.

Authors:  Porntip Intapiboon; Purilap Seepathomnarong; Jomkwan Ongarj; Smonrapat Surasombatpattana; Supattra Uppanisakorn; Surakameth Mahasirimongkol; Waritta Sawaengdee; Supaporn Phumiamorn; Sompong Sapsutthipas; Pasuree Sangsupawanich; Sarunyou Chusri; Nawamin Pinpathomrat
Journal:  Vaccines (Basel)       Date:  2021-11-23

9.  Maintenance of broad neutralizing antibodies and memory B cells 1 year post-infection is predicted by SARS-CoV-2-specific CD4+ T cell responses.

Authors:  Harikrishnan Balachandran; Chansavath Phetsouphanh; David Agapiou; Anurag Adhikari; Chaturaka Rodrigo; Mohamed Hammoud; Lok Bahadur Shrestha; Elizabeth Keoshkerian; Money Gupta; Stuart Turville; Daniel Christ; Cecile King; Sarah C Sasson; Adam Bartlett; Branka Grubor-Bauk; William Rawlinson; Anupriya Aggarwal; Alberto Ospina Stella; Vera Klemm; Michael M Mina; Jeffrey J Post; Bernard Hudson; Nicky Gilroy; Pam Konecny; Golo Ahlenstiel; Dominic E Dwyer; Tania C Sorrell; Anthony Kelleher; Nicodemus Tedla; Andrew R Lloyd; Marianne Martinello; Rowena A Bull
Journal:  Cell Rep       Date:  2022-01-19       Impact factor: 9.423

10.  Protocol for SARS-CoV-2 post-vaccine surveillance study in Australian adults and children with cancer: an observational study of safety and serological and immunological response to SARS-CoV-2 vaccination (SerOzNET).

Authors:  Amy Body; Elizabeth Ahern; Luxi Lal; Karen Gillett; Hesham Abdulla; Stephen Opat; Tracey O'Brien; Peter Downie; Stuart Turville; C Mee Ling Munier; Corey Smith; C Raina MacIntyre; Eva Segelov
Journal:  BMC Infect Dis       Date:  2022-01-20       Impact factor: 3.090
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.